Home/Pipeline/Undisclosed DDR Sensor Program(s)

Undisclosed DDR Sensor Program(s)

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

NERx Biosciences

About NERx Biosciences

NĒRx Biosciences is pioneering a novel approach in oncology by developing therapeutics that target DNA damage sensors, the initial detectors of genomic instability, rather than the downstream kinases commonly targeted in DDR inhibition. This pre-clinical stage company aims to create more effective and potentially safer cancer treatments by exploiting recent scientific advances in the underlying biology of various cancers. Backed by angel investors, the company is positioned to advance its programs with the goal of enhancing patient response and survival. Its success hinges on validating its unique mechanism and advancing candidates into clinical development.

View full company profile

Therapeutic Areas

Oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active